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er patient was 50 months (31–108). On susceptibility testing,
o resistance was detected in G-sensitive bacteria: the MCI
as <4 g/mL, except in two cases of CVCB due to methicillin-
esistant Staphylococcus aureus,  and one case with BC(−).
No patients had a diagnosis of ototoxicity. The mean trough
evel of G per patient was 0.17 g/mL (0.05–0.31). The mean
 lock per limb per patient was 3 mg (2–5), equivalent to
.1–1.7 mg/mL/limb depending on the volume of the limb
ccording to the type of catheter.
Patients diagnosed with CVCB: 11(8.7%). Patients admitted
o hospital for CVCB: 4 (3.2%). Number of CVCB/CVC/1000 days:
.17. CVC removed due to CVCB: 3 patients (2.4%). Mortal-
ty due to CVCB: 1 (0.8%). Number of CVCB: 15, Staphylococcus
ureus: 8; Staphylococcus epidermidis:  4; Escherichia coli: 1; Strepto-
occus bovis: 1, and BC(−): 1. CVC was removed due to recurrent
VCB in one patient, for failure to improve clinically of in one
atient, and due to BC(−) in one patient with clinical remis-
ion. There were no other CVCB complications (endocarditis,
pondylodiscitis), except in one patient who died due to sepsis.
Discussion. The scientiﬁc literature demonstrates that in
D patients, prophylaxis with post-HD antibiotic locking of
VC limbs, including G, reduces morbidity and mortality
rom bacterial infection associated with CVCB (number of
VCB/CVC/1000 days, mortality and hospital admission due
o CVCB) compared with patients with heparin lock alone.3
acterial resistance to G has been reported.4 However, our
xperience since July 2003 in patients with CVC attending
o the unit and treated with G locking in doses lower than
hose given in other units (a detail we consider fundamental
ue to iatrogenic effects), no bacterial resistance or ototoxic-
ty was demonstrated after 9 years of follow-up.3 Having seen
ur results, we  must refer to the publication by Beathar and
rbanes1 in which they rate the quality of care of a HD unit
ccording to the number of CVCB/CVC/1000 days it obtains
hen complete asepsis is employed, an excellent result being
 value ≤1. In our case, the practice of complete asep-
is + prophylaxis meant that the number of CVCB/CVC/1000
ays was 0.17. Although we  are unable to compare another
he relationship  between  seru
unction in  pediatric  renal  tran
elación  entre  niveles  de  NGAL  en
n  pacientes  pediátricos  trasplanta
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study, in 9 years, to obtain a mortality, removal of CVC, and
hospital admission due to CVCB of 0.8%, 2.4%, and 3.2%,
respectively, is an appreciable standard, obtained thanks to
G prophylaxis + universal asepsis. This is further underlined
by the absence of endocarditis or spondylodiscitis, except for
one patient who died due to sepsis. Strict complete asepsis5
for all handling procedures of CVC is integral to prophylaxis
in reducing morbidity and mortality from bacterial infection
associated with CVCB.
Conclusions. This prospective observational study of 9
years’ duration in 126 HD patients with a CVC showed: (1) Pro-
phylaxis with intraluminal G locking in CVC limbs does not
cause antibiotic resistance in microorganisms sensitive to the
antibiotic. (2) There were no diagnoses of clinical ototoxicity,
and (3) Prophylaxis with administration of low-dose G (com-
pared with higher doses in other studies)3 can result in the
absence of resistance and ototoxicity.
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We  previously serially measured the serum and urine neu-
trophil gelatinase associated lipocalin (NGAL) during the ﬁrst
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week after renal transplantation and found that mild ischemic
injury may increase this lipocalin.1 In this study, we investi-
gated the level of this marker after one month post-transplant
with the aim of ﬁnding a relationship between NGAL quanti-
ties and graft function.
Twenty-one pediatric renal transplant recipients without
any infection at the time of assessment were included in this
study. Glomerular ﬁltration rate was estimated by Schwartz
equation and DTPA scan concurrently. Scintigraphic measure-
ment of GFR was performed using an ADAC single-headed
gamma camera with the following formula:
Total renal uptake percent (%) = (k − b)/e − x
Pre-post – k: kidney count; b: background count; x: renal
depth; e: constant; : attenuation coefﬁcient of 99mTc in
soft tissue (0.153 cm−1); GFR = total renal uptake percent
(%) × 100 × 9.81270 − 6.82519.
The mean age of patients was 9.9 ± 3 years old. Nine
patients (43%) were male. The mean time from transplan-
tation was 6.8 ± 2.47 years. The mean serum creatinine was
1.16 ± 0.18 mg/dl. The mean Schwartz calculated GFR was
69.8 ± 12.2 cc/min/1.73 m2. The mean DTPA measured GFR
was 50.6 ± 16 cc/min/1.73 m2. All patients had GFR less than
90 cc/min/1.73 m2 by scan and Schwartz formula. The mean
serum NGAL was 140 ± 94 ng/ml (15–324 ng/ml). The mean
urine NGAL was 17.8 ng/ml (3.2–68 ng/ml).
We  assessed the correlation between serum NGAL and
serum creatinine, Schwartz GFR, and DTPA-related GFR. The
coefﬁcient of correlation with serum creatinine was 0.67
(P = 0.09), −0.2 (P = 0.3) with Schwartz GFR, and −0.26 (P = 0.46)
with DTPA GFR. Regarding urine NGAL, the correlation coefﬁ-
cient with serum creatinine was 0.2 (P = 0.37), −0.007 (P = 0.9)
with Schwartz GFR, and −0.24 (P = 0.48) with DTPA GFR.
We did not ﬁnd any signiﬁcant association between the
transplant time and serum NGAL (r = 0.05, P = 0.8) and urine
NGAL (r = 0.06, P = 0.77). Three patients had slow graft func-
tion in this study without need for dialysis in the ﬁrst week
post-transplant. The mean serum and urine NGAL was not
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different between patients with SGF and those without SGF
(for serum NGAL 106 vs 145.5 ng/ml and for urine NGAL 12.2
vs 21.6 ng/ml).
Studies have shown that expression of NGAL protein is
signiﬁcantly increased during ischemic insults in renal trans-
plant recipients with delayed graft function.2 Magnusson et al.
have shown that plasma NGAL levels were signiﬁcantly higher
than normal in renal transplant recipients.3 Malyszko et al.
also found a strong correlation between serum NGAL and
serum creatinine in 100 kidney transplant recipients.4
This study is the ﬁrst study in pediatric renal transplant
recipients in which the association between serum and urine
NGAL with graft function was assessed long term. We did
not ﬁnd any signiﬁcant association between the amounts of
NGAL in serum and urine with serum creatinine and GFR
estimated by Schwartz formula or measured by DTPA scan.
We think we  cannot use serum and urine NGAL as mark-
ers of graft function in pediatric renal transplant recipients,
but this result needs conﬁrmation by more  studies with more
cases.
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